Idarubicine
B-cell Childhood Acute Lymphoblastic Leukemia
Chinese Academy of Medical SciencesPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the B-cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE St. Jude Children's Research Hospital | Phase 3 | A |
MERCAPTOPURINE ANHYDROUS St. Jude Children's Research Hospital | Phase 3 | A |
PEGASPARGASE St. Jude Children's Research Hospital | Phase 3 | A |
METHOTREXATE St. Jude Children's Research Hospital | Phase 3 | BBB |
Cytosin-Arabinosid St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 44 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →